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In September, world leaders will meet at the United Nations in
New York to discuss non-communicable diseases.1 A decade
ago, at a similar meeting on HIV/AIDS, they created the Global
Fund for HIV/AIDS, Tuberculosis andMalaria—a revolutionary
new global health funding mechanism.2
The September meeting will focus on four leading
conditions—heart disease, cancer, diabetes, and respiratory
disease—that together cause more than half of all deaths in low
and middle income countries.3 Without action, the number of
premature deaths (age < 60) caused by non-communicable
diseases is expected to rise from 3.8 million each year to 5.1
million in poor countries by 2030, trapping a generation of
families in cycles of poverty and disease.4-6As Thomas Frieden,
director of the US Centers for Disease Control and Prevention,
recently stated, developing countries must immediately tackle
the rapid rise of non-communicable diseases because they will
“kill four times as many people by 2020 as infectious diseases.”7
Hopes are high that the UN meeting will mark a turning point
and avoid the belated response that hampered HIV strategies.
Progress on HIV required not only technical discussions about
which drugs work and how to make them cost effective; it also
needed to tackle the broader ethical, social, and political
dimensions of the HIV pandemic.8
Throughout the process, the imperative to act was presented as
one of social justice. It emphasised that HIVwas amanifestation
of inequalities in power and resources. Efforts by drug
companies to protect long term patents on antiretroviral drugs
were met by activists fighting for access to treatment and
declaring that human lives in poor countries were just as
valuable as those in rich ones.
Misconception and neglect
Non-communicable diseases, by contrast, remain neglected
despite their social parallels to HIV.9-11Aswith HIV, discussions
are plagued by misconceptions. Although they have been
thought of as diseases of the wealthy, this is simply incorrect
(box).
Another common fallacy is that non-communicable diseases
stem from amoral failure—that weakness of will leads to obesity
or sedentary lifestyles. But people in many parts of the world
face major barriers to making healthy choices and face powerful
pressures to adopt unhealthy ones.15
Pervasive fallacies have led to serious under-budgeting for
non-communicable diseases (box). As the health minister of
Uganda put it, “We knowwhat to do [but] we have no budget.”15
The paradoxes are obvious to observers in developing countries.
Guyana’s health minister, Leslie Ramsammy, pointed to the
fact that the millennium development goals did not include
non-communicable diseases even though they account for 60%
of global deaths. “Most of the morbidity and mortality caused
by the chronic diseases are preventable. [This is] a serious
omission,” he said. 15
Because non-communicable diseases are not part of the goals,
development agencies fail to prioritise them; health ministers
in turn do not seek support for prevention and control because
of the lack of available funding. Little research can be done on
how to prevent and treat these conditions, and this allows cynics
to argue there is weak evidence for intervention—a Catch 22
situation is created.
Yet proved and cost effective interventions do exist (box).19 For
example, the World Bank says tobacco and alcohol taxes,
smoking bans to reduce deaths, and treatment of acute
myocardial infarction with aspirin and β blockers are among
the most cost effective measures for disease control available
in low income countries.20
Vested interests
So why has there been no clear response to non-communicable
diseases? One crucial difference fromHIV is that there has been
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Epidemiology of non-communicable diseases
• The common non-communicable diseases increasingly affect the poorest in low and middle income countries, just
as in high income nations3 12
• Women aged 15-49 in sub-Saharan Africa are four times more likely to die or experience disability from a
non-communicable disease than women in high income countries13
• High blood pressure is the second leading risk factor for death in low income countries (behind child underweight),
and high blood glucose is the fifth14
Funding gap
• One survey of health ministers worldwide found that only about a third had even a single budget line for
non-communicable diseases16
• Overall, less than 3% of global health aid has been designated for non-communicable diseases17
• WHO—which has provided the strongest support to NCDs among global institutions—allocates less than 10% of its
budget to these diseases18
Evidence based action
• Tobacco and alcohol tax increases have been shown to reduce consumption as well as raise revenue for
governments21-23
• A meta-analysis of alcohol tax studies estimated that a doubling of the price of alcohol beverages would reduce
alcohol related mortality by 35%, traffic crash deaths by 11%, sexually transmitted diseases by 6%, violence by 2%,
and crime by 1.4%24
• Salt reduction reduces blood pressure and risks of cardiovascular disease. Regulating salt intake could save billions
in healthcare costs annually 25
no strong base of advocates to tackle the root social causes of
illness. Advocacy on non-communicable diseases has been
described by young people as “dull” and “uninspiring,” lacking
an emphasis on social justice or inequality and missing a sense
of outrage and urgency against continued inaction.
As a result, much of the agenda is being written by powerful
vested interests.Margaret Chan, director general ofWHO, stated
that “Today, many of the threats to health that contribute to
NCDs come from corporations that are big, rich and powerful,
driven by commercial interests, and far less friendly to health.
Today, more than half of the world’s population lives in an
urban setting. Slums need corner food stores that sell fresh
produce, not just packaged junk with a cheap price and a long
shelf-life.”26
At a preparatory meeting in New York representatives of the
United States, Europe, and key Western allies, blocked
consensus on action on non-communicable diseases after
lobbying from the alcohol, food, tobacco, and drug industries.
Negotiations have now stalled. When asked why Michelle
Obama’s successful childhood obesity programmes in the US
should not be modelled in developing countries, a US official
responded that they might harm American exports.
The current draft of the declaration on non-communicable
diseases has no time bound commitments; does not allocate
resources to prevent and control these diseases; and does not
include language focusing on the most cost effective fiscal and
regulatory interventions.
TheNCDAlliance, a leading non-governmental advocacy group,
highlights the “unwillingness” of donor countries to call for
increased resources for non-communicable diseases and for “the
need for evidence-based fiscal policies such as increased taxation
on tobacco.”
Food companies have hired US President Obama’s former
communications director, Anita Dunn, to lead lobbying efforts
on food regulations; these industries look to low and middle
income countries as their greatest growth markets.27
There is also evidence that food companies have worked through
US diplomats to secure a more favourable economic and legal
environment in developing countries. McDonald’s sought to
delay the implementation of new US free trade legislation until
El Salvador appointed new judges to resolve an ongoing court
dispute.28
Should the industries that profit from unhealthy products be
viewed as trusted partners and have a seat at the table during
public health negotiations? At recent UN civil society
hearings—the main opportunity for advocates to shape the final
UN political declaration—representatives from food (including
the International Food and Beverage Alliance) and alcohol
industries (including Anheuser-Busch, SABMiller, and the
Global Alcohol Producers group) were among the main
representatives of civil society. Alcohol industry representatives
said at a preparatory meeting: “We will do anything as long as
it is voluntary.”
Corporate influence takes many, often subtle and indirect forms.
Philip Morris’s latest campaign, “Project Sunrise,” explicitly
aims to “weaken tobacco control by working with it,” funding
front groups and exploiting differences of opinion within the
tobacco control movement to “create schisms—force them to
fight among themselves.”29
Where collaboration does not work, direct threats may be used.
After WHO released its report on diet, physical activity, and
health in 2003, which recommended reduced sugar intake, the
sugar industry threatened that it would lobby the US to cut off
its financial support to WHO. Three of Washington’s largest
lobbying firms nowwork for the food industry.30Vested interests
also pose a problem for the non-governmental organisations
that are most actively engaged in the UN civil society hearings.
Many receive a considerable proportion of their funding from
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drug companies or food companies, potentially compromising
their ability to argue for greater use of generic drugs or taxation
and regulatory interventions.31
Policy debates may also be shaped by decisions on what is
prioritised and what is not in global health. For example, the
Bill and Melinda Gates Foundation, which funds more than
$3.5bn of global health research each year, offers less than 3%
of its funding for research into non-communicable diseases,32 33
while holding large stocks in food and drink companies (owning
10% of global Coca-Cola stock, for example).31
Like the HIV meeting, the UN high level meeting on
non-communicable diseases is a battleground, pitting public
interests against powerful private ones. But unlike the HIV
activism of the past, the voices of people affected by
non-communicable diseases are mostly quiet. Whether the
meeting encourages the emergence of a global social movement
for change will shape the future of our health for years to come.
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